

Summary

Guide-Line of the Radio-Iodine (¹³¹I) Therapy in Graves' Disease and Thyroid Cancer

Yutaka MORI*¹, Kiyoko KUSAKABE*², Katsuji IKEKUBO*³, Naofumi ISHIKAWA*⁴,
Kunihiro NAKADA*⁵, Shinichi KANAYA*², Takashi MISAKI*⁶, Kunihiro YOKOYAMA*⁷,
Atsushi KUBO*⁸, Tatsuya HIGASHI*⁹, Kouichi ITOU*⁴, Yasushi NOGUCHI*¹⁰,
Shinsaku TSUCHIMOCCHI*¹¹ and Takashi TOGAWA*¹²

**¹Department of Radiology, The Jikei University School of Medicine*

**²Department of Radiology, Tokyo Women's Medical University*

**³Hyogo Health Service Association*

**⁴Department of Internal Medicine, Ito Hospital*

**⁵Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine*

**⁶Tenri Hospital*

**⁷Department of Nuclear Medicine, Kanazawa University Graduate School of Medicine*

**⁸Department of Radiology, School of Medicine, Keio University*

**⁹Department of Nuclear Medicine, Kyoto University Graduate School of Medicine*

**¹⁰Noguchi Hospital*

**¹¹Department of Radiology, Kagoshima University Graduate School of Medicine*

**¹²Division of Nuclear Medicine, Chiba Cancer Center*

Radio-iodine (¹³¹I) therapy has been using in Graves' disease and well differentiated thyroid cancer. The rules of control in the discharge from radio-isotope hospital were notified in 1999 in Japan. Guide-line of the ¹³¹I therapy in Graves' disease and thyroid

cancer were prepared by sub-group of Japanese Society of Nuclear Medicine.

Key words: Graves' disease, Hyperthyroidism, Thyroid cancer, Radio-iodine therapy, Japanese guide-line.